Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis.

IF 2.6 4区材料科学 Q3 MATERIALS SCIENCE, MULTIDISCIPLINARY

Beilstein Journal of Nanotechnology Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI:10.3762/bjnano.15.89

Damai Ria Setyawati, Fransiska Christydira Sekaringtyas, Riyona Desvy Pratiwi, A'liyatur Rosyidah, Rohimmahtunnissa Azhar, Nunik Gustini, Gita Syahputra, Idah Rosidah, Etik Mardliyati, Tarwadi, Sjaikhurrizal El Muttaqien

{"title":"Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis.","authors":"Damai Ria Setyawati, Fransiska Christydira Sekaringtyas, Riyona Desvy Pratiwi, A'liyatur Rosyidah, Rohimmahtunnissa Azhar, Nunik Gustini, Gita Syahputra, Idah Rosidah, Etik Mardliyati, Tarwadi, Sjaikhurrizal El Muttaqien","doi":"10.3762/bjnano.15.89","DOIUrl":null,"url":null,"abstract":"Over recent decades, nanomedicine has played an important role in the enhancement of therapeutic outcomes compared to those of conventional therapy. At the same time, nanoparticle drug delivery systems offer a significant reduction in side effects of treatments by lowering the off-target biodistribution of the active pharmaceutical ingredients. Cancer nanomedicine represents the most extensively studied nanotechnology application in the field of pharmaceutics and pharmacology since the first nanodrug for cancer treatment, liposomal doxorubicin (Doxil®), has been approved by the FDA. The advancement of cancer nanomedicine and its enormous technological success also included various other target diseases, including hepatic fibrosis. This confirms the versatility of nanomedicine for improving therapeutic activity. In this review, we summarize recent updates of nanomedicine platforms for improving therapeutic efficacy regarding liver fibrosis. We first emphasize the challenges of conventional drugs for penetrating the biological barriers of the liver. After that, we highlight design principles of nanocarriers for achieving improved drug delivery of antifibrosis drugs through passive and active targeting strategies.","PeriodicalId":8802,"journal":{"name":"Beilstein Journal of Nanotechnology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346304/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beilstein Journal of Nanotechnology","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.3762/bjnano.15.89","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Over recent decades, nanomedicine has played an important role in the enhancement of therapeutic outcomes compared to those of conventional therapy. At the same time, nanoparticle drug delivery systems offer a significant reduction in side effects of treatments by lowering the off-target biodistribution of the active pharmaceutical ingredients. Cancer nanomedicine represents the most extensively studied nanotechnology application in the field of pharmaceutics and pharmacology since the first nanodrug for cancer treatment, liposomal doxorubicin (Doxil^®), has been approved by the FDA. The advancement of cancer nanomedicine and its enormous technological success also included various other target diseases, including hepatic fibrosis. This confirms the versatility of nanomedicine for improving therapeutic activity. In this review, we summarize recent updates of nanomedicine platforms for improving therapeutic efficacy regarding liver fibrosis. We first emphasize the challenges of conventional drugs for penetrating the biological barriers of the liver. After that, we highlight design principles of nanocarriers for achieving improved drug delivery of antifibrosis drugs through passive and active targeting strategies.

查看原文本刊更多论文

应用纳米药物治疗肝纤维化的最新进展。

近几十年来，与传统疗法相比，纳米医学在提高治疗效果方面发挥了重要作用。同时，纳米颗粒给药系统通过降低活性药物成分的脱靶生物分布，大大减少了治疗的副作用。自第一种用于癌症治疗的纳米药物脂质体多柔比星（Doxil®）获得美国食品及药物管理局批准以来，癌症纳米药物是制药学和药理学领域研究最为广泛的纳米技术应用。癌症纳米药物的发展及其巨大的技术成功还包括其他各种目标疾病，包括肝纤维化。这证实了纳米药物在提高治疗活性方面的多功能性。在本综述中，我们总结了纳米药物平台在改善肝纤维化疗效方面的最新进展。我们首先强调了传统药物在穿透肝脏生物屏障方面所面临的挑战。然后，我们强调了纳米载体的设计原则，以通过被动和主动靶向策略实现抗肝纤维化药物的更好给药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Beilstein Journal of Nanotechnology NANOSCIENCE & NANOTECHNOLOGY-MATERIALS SCIENCE, MULTIDISCIPLINARY

CiteScore

5.70

自引率

3.20%

发文量

109

审稿时长

2 months

期刊介绍： The Beilstein Journal of Nanotechnology is an international, peer-reviewed, Open Access journal. It provides a unique platform for rapid publication without any charges (free for author and reader) – Platinum Open Access. The content is freely accessible 365 days a year to any user worldwide. Articles are available online immediately upon publication and are publicly archived in all major repositories. In addition, it provides a platform for publishing thematic issues (theme-based collections of articles) on topical issues in nanoscience and nanotechnology. The journal is published and completely funded by the Beilstein-Institut, a non-profit foundation located in Frankfurt am Main, Germany. The editor-in-chief is Professor Thomas Schimmel – Karlsruhe Institute of Technology. He is supported by more than 20 associate editors who are responsible for a particular subject area within the scope of the journal.